◎ Sugi Atlas

Atlas / Drug / Fluvoxamine

Fluvoxamine

drug
On this page

Also known as FluvoxaminaN06AB08SID11111173SID26751469SID90340960SID50100910SID50103976SID144204388SID170464809

Summary

Fluvoxamine (CHEMBL814) is an approved small-molecule antidepressant (ATC N06AB08) targeting SIGMAR1 and SLC6A4; indicated across 16 conditions including melancholia and depressive disorder.

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: N06AB08
  • Targets: 2 (SIGMAR1, SLC6A4)
  • Indications: 16 conditions
  • Clinical trials: 57
  • Chemistry: 318.33 Da · C15H21F3N2O2

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL814
NameFluvoxamine
TypeSmall molecule
Max phase4
FDA approvedyes
PubChem CID5324346
ChEBICHEBI:5138
ATCN06AB08
Molecular formulaC15H21F3N2O2
Molecular weight318.33
InChIKeyCJOFXWAVKWHTFT-XSFVSMFZSA-N

SMILES: COCCCC/C(=N\OCCN)/C1=CC=C(C=C1)C(F)(F)F

IUPAC name: 2-[(E)-[5-methoxy-1-[4-(trifluoromethyl)phenyl]pentylidene]amino]oxyethanamine

ChEBI definition: An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.

Pharmacological roles (ChEBI): antidepressant, serotonin uptake inhibitor, anxiolytic drug.

Also known as: Fluvoxamina, Fluvoxamine, N06AB08, fluvoxamine, SID11111173, SID26751469, SID90340960, SID50100910, SID50103976, SID144204388, FLUVOXAMINE, SID170464809

Parent form; salt/anhydrous children: CHEMBL1409

Patent coverage: 8,372 distinct patent families (31,662 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
SIGMAR1sigma non-opioid intracellular receptor 1Binding7.442.6%Q99720
SLC6A4SERTInhibition8.660.7%P31645

Broader ChEMBL bioactivity targets: 23 (assay-derived). Sample: Cytochrome P450 1A2, Survival motor neuron protein, Inositol monophosphatase 1, Sodium channel protein type 5 subunit alpha, Sodium-dependent noradrenaline transporter, Sodium-dependent serotonin transporter, Alpha-1A adrenergic receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Kappa-type opioid receptor, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 25 potent at pChembl ≥ 5 of 41 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
SLC6A38.84Ki1.46nMCHEMBL_ACT_118577
SLC6A48.51Ki3.08nMCHEMBL_ACT_1052211
SLC6A48.42IC503.8nMCHEMBL_ACT_22850860
SLC6A48.4AC504nMCHEMBL_ACT_25150157
Q9R0C97.44Ki36nMCHEMBL_ACT_10972887
SIGMAR17.44Ki36nMCHEMBL_ACT_12180126
Q9R0C97.44Ki36nMCHEMBL_ACT_22850842
CYP2C197Potency100nMCHEMBL_ACT_4014645
CYP2C197AC50100nMCHEMBL_ACT_6004252
CYP1A26.8AC50158.5nMCHEMBL_ACT_6012013
SLC6A46.34Ki458nMCHEMBL_ACT_23305381
P316526.27IC50540nMCHEMBL_ACT_1271846
ADRA1A5.59AC502547nMCHEMBL_ACT_25137824
KCNH25.51IC503100nMCHEMBL_ACT_15257959
KCNH25.4AC504000nMCHEMBL_ACT_25117608
O355055.31IC504900nMCHEMBL_ACT_15257929
O355055.31IC504900nMCHEMBL_ACT_15373238
NFKB15.25Potency5623nMCHEMBL_ACT_3672757
NFKB15.25Potency5623nMCHEMBL_ACT_4586038
ADRA1A5.22AC506000nMCHEMBL_ACT_25217939
CYP2D65.1Ki8000nMCHEMBL_ACT_15456083
SMN15.1Potency7943nMCHEMBL_ACT_3877662
Q5U3Y75.07Ki8439nMCHEMBL_ACT_22850816
CYP2C95.07Ki8500nMCHEMBL_ACT_384514
P976975Potency10000nMCHEMBL_ACT_4421343

Target pathways

Aggregated over 2 target gene(s): SIGMAR1, SLC6A4.

Top Reactome pathways

10 total, by targets touching each:

PathwayTargetsGenes
Neurotransmitter clearance1SLC6A4
Transmission across Chemical Synapses1SLC6A4
Neuronal System1SLC6A4
Disease1SIGMAR1
Serotonin clearance from the synaptic cleft1SLC6A4
SLC-mediated transport of neurotransmitters1SLC6A4
Infectious disease1SIGMAR1
Potential therapeutics for SARS1SIGMAR1
SARS-CoV Infections1SIGMAR1
Viral Infection Pathways1SIGMAR1

Dominant GO biological processes

GO termTargets
lipid transport1
nervous system development1
regulation of neuron apoptotic process1
protein homotrimerization1
response to alcohol1
regulation of postsynapse assembly1
G protein-coupled opioid receptor signaling pathway1
response to hypoxia1
neurotransmitter transport1
amino acid transport1
response to nutrient1
memory1
circadian rhythm1
response to xenobiotic stimulus1
response to toxic substance1

Indications & clinical

Indications

16 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
melancholia4MONDO:0002444EFO:1002014
depressive disorder4MONDO:0002050MONDO:0002050
autism3MONDO:0005260EFO:0003758
obsessive-compulsive disorder3MONDO:0008114EFO:0004242
anxiety3MONDO:0011918EFO:0005230
separation anxiety disorder3MONDO:0001098EFO:1001916
social phobia3MONDO:0001247EFO:1001917
dementia3MONDO:0001627HP:0000726
severe acute respiratory syndrome3MONDO:0005091MONDO:0100096
generalized anxiety disorder3MONDO:0001942EFO:1001892
panic disorder2MONDO:0005383EFO:0004262
long COVID-192MONDO:0100233MONDO:0100233
neoplasm1MONDO:0005070EFO:0000616

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 57.

Phase distribution

PhaseTrials
PHASE120
Not specified12
PHASE310
PHASE48
PHASE26
PHASE2/PHASE31

Top trials by phase / activity

NCTPhaseStatusTitle
NCT01764867PHASE4UNKNOWNAlgorithm Guided Treatment Strategies for Major Depressive Disorder
NCT02016261PHASE4COMPLETEDStudy to Evaluate Cognitive Functioning in Remitted Depression During Treatment With Fluvoxamine
NCT02022709PHASE4COMPLETEDEfficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
NCT02194075PHASE4COMPLETEDMethylphenidate Hydrochloride Controlled-Release Tablets Augmentation Strategy for Patients With Obsessive Compulsive Disorder
NCT03219008PHASE4UNKNOWNMulti-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics
NCT03779789PHASE4COMPLETEDVortioxetine in the Elderly vs. Selective Serotonin Reuptake Inhibitors (SSRIs): a Pragmatic Assessment
NCT04963257PHASE4UNKNOWNSertraline Combined With Fluvoxamine in the Treatment of Refractory Obsessive-compulsive Disorder
NCT05087381PHASE4COMPLETEDRandomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community
NCT06969287PHASE3RECRUITINGMitigating Delirium With Fluvoxamine Treatment for Non-Cardiac Surgery
NCT07359482PHASE3NOT_YET_RECRUITINGsElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19
NCT00000389PHASE3COMPLETEDTreatment for Anxiety in Children
NCT00655174PHASE3COMPLETEDFluvoxamine and Sertraline in Childhood Autism - Does SSRI Therapy Improve Behaviour and/or Mood?
NCT02374567PHASE3TERMINATEDPharmacovigilance in Gerontopsychiatric Patients
NCT04510194PHASE3COMPLETEDCOVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)
NCT04668950PHASE3COMPLETEDFluvoxamine for Early Treatment of Covid-19 (Stop Covid 2)
NCT04885530PHASE3COMPLETEDACTIV-6: COVID-19 Study of Repurposed Medications
NCT05874037PHASE2/PHASE3COMPLETEDFluvoxamine for Long COVID-19
NCT05890586PHASE3COMPLETEDACTIV-6: COVID-19 Study of Repurposed Medications - Arm B (Fluvoxamine)
NCT05894564PHASE3COMPLETEDACTIV-6: COVID-19 Study of Repurposed Medications - Arm E (Fluvoxamine 100)
NCT04539951PHASE2RECRUITINGPragmatic Trial of Obsessive-compulsive Disorder
NCT04160377PHASE2UNKNOWNA Clinical Trial of Fluvoxamine for Melancholia
NCT04342663PHASE2COMPLETEDA Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection
NCT04711863PHASE2SUSPENDEDFluvoxamine for Adults With Mild to Moderate COVID-19
NCT04718480PHASE2COMPLETEDFluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients
NCT05216614PHASE2WITHDRAWNFluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia
NCT00175981PHASE1COMPLETEDInteraction Between Fluvoxamine and Sildenafil
NCT00456560PHASE1COMPLETEDAV650 Drug-Drug Interaction Study
NCT01269333PHASE1COMPLETEDImpact of Omeprazole and Fluvoxamine on Platelet Response to Clopidogrel
NCT01396720PHASE1COMPLETEDImpact of Citalopharm and Fluvoxamine on Platelet Response to Clopidogrel
NCT01540500PHASE1COMPLETEDPharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
NCT01665404PHASE1COMPLETEDA Study of the Effect of Fluvoxamine on the Pharmacokinetics of RO4917523 in Healthy Volunteers
NCT01700270PHASE1COMPLETEDPharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
NCT01704638PHASE1COMPLETEDKinetics of Fluvoxamine and Digoxin in Subjects With Different MDR1 Genotypes
NCT01707407PHASE1COMPLETEDA Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects
NCT01908296PHASE1COMPLETEDStudy to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers
NCT02853136PHASE1COMPLETEDInfluence of Fluvoxamine on the Pharmacokinetics of BI 409306
NCT03340662PHASE1COMPLETEDStudy Evaluating the Effects of Food, Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of CC-122
NCT03432793PHASE1COMPLETEDDrug-Drug Interaction (DDI) Study for TD-9855
NCT03930602PHASE1COMPLETEDStudy to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165
NCT04478513PHASE1COMPLETEDA Study to Assess the Effect of Fluvoxamine and Smoking on Pharmacokinetics ( the Movement of Drugs Within the Body) of AZD4635 in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

510 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
DihydroergotamineChEMBL + PubChemPhase 4 (approved)SIGMAR1, SLC6A4
AMIODARONEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
AMITRIPTYLINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
ASTEMIZOLEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
AZELASTINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
BENZTROPINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
BREXPIPRAZOLEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
BROMHEXINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
BUTENAFINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
CHLORPROMAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
CINACALCETChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
CINNARIZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
CISAPRIDEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
CITALOPRAMChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
CLEMASTINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
CLOMIPRAMINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
CLOZAPINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
COCAINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
DEXCHLORPHENIRAMINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
DEXTROMETHORPHANChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
DOBUTAMINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
DOXEPINChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
ECONAZOLEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
FLUOXETINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
FLUPHENAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
HALOPERIDOLChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
ILOPERIDONEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
KETANSERINChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
LABETALOLChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
LEVOBUNOLOLChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
LOPERAMIDEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
MAZINDOLChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
MEPAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
NAFTIFINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PAROXETINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PERHEXILINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PHENTOLAMINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PIPAMAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PITOLISANTChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PROCHLORPERAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PROMAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PROMETHAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PROPAFENONEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PROPRANOLOLChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
PYRILAMINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
RALOXIFENEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
RISPERIDONEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
SERTRALINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
SULOCTIDILChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
TAMOXIFENChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
TEGASERODChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
TERCONAZOLEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
THIORIDAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
TOLTERODINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
TRAZODONEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
TRIFLUOPERAZINEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
VILAZODONEChEMBLPhase 4 (approved)SIGMAR1, SLC6A4
ENCLOMIPHENEChEMBLPhase 3SIGMAR1, SLC6A4
MOSAPRIDEChEMBLPhase 3SIGMAR1, SLC6A4
OPIPRAMOLChEMBLPhase 3SIGMAR1, SLC6A4

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot